@twillo Good question. I started with Q4 2024 data and worked from there.
In Q4 2024, CRMD had total DefenCath revenue of $31.2M, with 87% ($27.1M) coming from a single customer. Based on conference call commentary, this customer is almost certainly U.S. Renal Care (the only dialysis customer mentioned by name and referred to as having ~80% penetration).
U.S. Renal Care is the 3rd largest dialysis provider in the U.S. I estimate they represent approximately 4% of the national dialysis market. Management has stated they’ve achieved roughly 80% penetration at U.S. Renal Care and that this represents near-maximum saturation for any customer.
If U.S. Renal Care (4% of market) generates $27.1M quarterly at 80% penetration:
$27.1M ÷ 4% = $677.5M per quarter
This implies a total addressable market of ~$2.7B annually at 80% penetration across all dialysis centers.
Conservative Adjustment
I don’t believe other dialysis organizations will achieve 80% penetration as quickly or consistently as U.S. Renal Care (likely an early adopter with strong relationship). So I applied a significant haircut and estimated:
$500M per quarter = $2B annually
Key Assumptions & Risks
Bearish considerations (could make my estimate too high):
- U.S. Renal Care might actually represent >4% of the market, making my extrapolation too aggressive
- Other dialysis organizations may never reach 80% penetration due to weaker relationships, competitive products, or slower adoption curves
- Some of the sales to U.S. Renal Care in Q4 were them raising their inventory levels
Bullish considerations (could make my estimate too low):
- This analysis excludes hospital sales entirely (DefenCath is also approved for hospital use)
- No international revenue included
Bottom Line
My $2B target assumes DefenCath can eventually achieve ~60% average penetration across the broader dialysis market (vs. 80% at U.S. Renal Care).
Drew